Paradigm banks $5.75 million in tax refunds to bolster Phase 3 war chest
Paradigm Biopharmaceuticals (ASX:PAR), a late-stage drug development company, has received combined cash receipts of approximately $5.75 million from two Australian Government tax sources.
The refunds, disclosed on 22 July 2026, strengthen the company’s balance sheet as it progresses its pivotal Phase 3 osteoarthritis clinical program.
When big ASX news breaks, our subscribers know first
Breaking down the $5.75 million in receipts
The total comprises two distinct events, and each carries its own source and prior-period reference.
The first is an FY25 Research and Development (R&D) Tax Incentive refund of $4,817,677, inclusive of $59,579 of interest earned. This relates to the financial year ended 30 June 2025.
The second is a separate refund of $927,317, including $85,083 of interest, following an amended income tax assessment for the financial year ended 30 June 2023.
| Source | Relevant Period | Amount | Interest Included | Notes |
|---|---|---|---|---|
| R&D Tax Incentive refund | FY25 (year ended 30 June 2025) | $4,817,677 | $59,579 | Refundable offset for eligible R&D expenditure |
| Amended income tax assessment | FY23 (year ended 30 June 2023) | $927,317 | $85,083 | Prior-year amended assessment refund |
| Combined total | – | ~$5.75 million | – | Combined cash receipts |
What the R&D Tax Incentive means for investors
The Australian Government’s Research and Development (R&D) Tax Incentive is designed to encourage innovation by supporting Australian companies undertaking eligible research and development activities. Under the programme, qualifying companies can receive refundable tax offsets for eligible R&D expenditure.
Why the timing matters for the Phase 3 program
The receipts arrive as Paradigm continues to execute its stated strategic priorities. The company is progressing its pivotal Phase 3 clinical program evaluating injectable pentosan polysulfate sodium (iPPS) for the treatment of knee osteoarthritis.
Phase 3 enrolment completion was confirmed at 538 participants across 65 clinical sites in four countries, surpassing the original 466-patient target, with top-line results now on track for Q1 2027.
According to the company, the funds support ongoing regulatory and New Drug Application (NDA) activities, alongside manufacturing and global partnering initiatives. Management identified the following priorities:
-
Advancing the pivotal Phase 3 osteoarthritis program
-
Supporting regulatory and NDA activities
-
Manufacturing initiatives
-
Global partnering initiatives
Paul Rennie, Managing Director
“The receipt of the FY25 R&D Tax Incentive refund, together with the amended FY23 income tax refund, further strengthens Paradigm’s financial position as we continue to execute on our strategic priorities. These funds support the continued advancement of our pivotal Phase 3 osteoarthritis program, while also providing additional flexibility as we progress regulatory, manufacturing and global partnering initiatives.”
The combined receipts reinforce the balance sheet at a capital-intensive stage of late-stage clinical development, where funding flexibility can support progress across regulatory, manufacturing and partnering workstreams.
The tax receipts add to a balance sheet already bolstered by an upsized $14 million placement completed in April 2026, which brought pro forma cash to approximately $45 million and was designed to carry the company through its Phase 3 interim analysis without further dilutive equity.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already ahead of the market and never miss a market-moving announcement. Click the “Free Alerts” button at Big News Blast to start receiving real-time coverage today.